Tag: InspireMD
InspireMD receives IDE approval from US FDA for CGUARDIANS II pivotal...
InspireMD has announced that the US Food and Drug Administration (FDA) approval of the company’s investigational device exemption (IDE) application to initiate the CGUARDIANS...
LINC 2024: C-GUARDIANS data represent lowest event rates in published trials...
New data from the C-GUARDIANS pivotal investigational device exemption (IDE) trial support consideration of carotid artery stenting (CAS) with the CGuard embolic prevention stent...
InspireMD presents positive 30-day follow-up results from C-GUARDIANS clinical trial
InspireMD recently presented 30-day results from the C-GUARDIANS US investigational device exemption (IDE) clinical trial evaluating its CGuard embolic prevention stent (EPS) system for...
InspireMD announces the inclusion of its CGuard carotid stent in CREST-2...
InspireMD has announced that its CGuard embolic prevention stent system (EPS) will be included as a device option for stenting in CREST-2 (Carotid revascularisation...
SIBERIA trial: Positive one-month results for embolic prevention system
InspireMD has announced positive interim results from the SIBERIA trial, an investigator-initiated study of the CGuard embolic prevention system (EPS). The data were presented...
InspireMD announces expansion of its distribution network for CGuard EPS in...
InspireMD has announced it has signed Diverse Devices as its exclusive distributor for Australia and New Zealand, and has signed Do Gia Production...
Twelve-month PARADIGM study data demonstrate benefit of CGuard Embolic Prevention System...
InspireMD has announced 12-month follow up data from PARADIGM-101 study of the CGuard Embolic Prevention System (EPS), which were presented at the Transcatheter Cardiovascular...
